Determination of Radiochemical Purity of 99mTc-DTPA Using One-System Method of Paper Chromatography
Maskur Maskur, Enny Lestari, Amal Rezka Putra, Dede Kurniasih, Endang Sarmini, Yayan Tahyan, Adang Hardi Gunawan, Arni Aries
J. Pure App. Chem. Res. Vol 8, No 2 (2019), pp.
Submitted: April 06, 2019     Accepted: June 12, 2019     Published: June 12, 2019

Abstract


Cover Image

The more efficient and effective quality control techniques for 99mTc-DTPA are needed because 99mTc has a short half-life of around 6.0 hours. We have succeeded in developing a one-system of TLC for radiochemical purity testing system that is faster and more practical. Two-system method of TLC for radiochemical purity testing uses mobile phase of methyl ethyl ketone as an A and 0.9% sodium chloride solution as a B. One-system method uses the mobile phase of a mixture solution of acetone and 0.9% sodium chloride. In this study, the determination of radiochemical purity of the one-system of TLC has been successfully developed using the Whatman-1 paper stationary phase and the mixed mobile phase between acetone and 0.9% sodium chloride solution. The mobile phase of acetone: 0.9% sodium chloride with a ratio of 9:1 shows the most optimum results. This phase can separate 99mTc-DTPA (Rf = 0.4-0.6) from 99mTcO4- (Rf = 0.9-1.0) and 99mTcO2 (Rf = 0.0-0.1) as radiochemical impurities. This result shows that the one-system of TLC method can be used for radiochemical purity testing of 99mTc-DTPA radiopharmaceutical kits. This method can completely separate the product compound (99mTc-DTPA) from its impurities (99mTcO2 and 99mTcO4-).


Keywords : Radiochemical purity; 99mTc-DTPA; 99mTc; one-system of TLC; two-system of TLC
Full Text: PDF


References


[1] Fitri Imelda, Endang Susalit, M Bonar M Marbun, C. M. R., J. Penyakit Dalam Indonesia, 2017, 4, 128–136.

[2] Maskur, Purwoko, Chairuman, Yono S., Pros. Semin. Nas. Kim. FMIPA Univ. Negeri Surabaya, 2015, 11–18.

[3] Stefanus Santosa, Agus Widjanarko, C. S., J. Pseudocode III, 2016, 163–170.

[4] Sevin Ayaz. J. Clin. Anal. Med., 2017, 8, 8–11.

[5] Abdel, M. & Hamed, G. Iran. J. Nucl. Med., 2017, 25 (1), 17–22.

[6] Piepsz, A., Eur. J. Radiol., 2002, 43, 146–153 (2002).

[7] Delima, E. T. et al. Bul. Penelit. Kesehat., 2014, 45, 17–26.

[8] Levey, A. S. & Coresh, J. Lancet, 2012, 379, 165–180.

[9] Wiguno Prodjosudjadi, A. S., J. Ethn. Dis., 2009, 19, 33–36.

[10] Williams, J.K.Y., Nurs. Clin. NA, 2017, 52, 575–587.

[11] Serdar Savas SGul, Zekiye Hasbek, Taner Erselcan, Melih Akyol, B. T. Acta Medica Mediter., 2015, 31, 1247–1252.

[12] Kim, Y., Ha, S., So, Y. & Lee, W. W. Eur Radiol., 2014, 24, 413–422.

[13] Razaq, T., Nisar, H., Roohi, S., Shehzad, A. & Ahmad, I. Iran J Nucl Med, 2017, 25, 122–128.

[14] Taylor, A. T. J. Nucl. Med., 2014, 55, 1–9.

[15] Maskur, Enny Lestari, Endang Sarmini, Yayan Tahyan, Amal Rezka Putra, Dede Kurniasih, A. H. G. Urania, 2017, 23, 57–68.

[16] Sadeghpour, H., Alavi, M., Shahedi, M., Entezarmahdi, S. M. & Sakhteman, A., Trends Pharm. Sci., 2015, 1, 15–19.

[17] Shankar Vallabhajosula, Ronan P. Killeen, and J. R. O. YSNUC, 2010, 40, 220–241.

[18] Zimmerman, B. E., Herbst, C., Norenberg, J. P. & Woods, M. J. Appl. Radiat. Isot., 2006, 64, 1142–1146.

[19] Millar, A. M., Brien, Ã. L. M. O., Beattie, L. A. & Craig, F. J. Label Compd. Radiopharm., 2010, 53, 11–14.

[20] Leonardi, N. M., Casale, G. A., Nicolini, J., Zubata, P. D. & Zubillaga, M. B. J. Nucl. Med. Technol., 2015, 40, 271–275.

[21] Candela, M., Tesán, F. C., Leonardi, N. M., Zubillaga, M. B. & Salgueiro, M. J. Appl. Radiat. Isot., 2013, 82, 322–324.

[22] Korkmaz, M. & Özer, A. Y. J. Pharm. Sci., 1996, 22, 105–110.

[23] Maioli, C., Lucignani, G., Strinchini, A., Tagliabue, L. & Del Sole, A. Acta Biomed., 2017, 88, 49–56.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.